Prophylactic Efficacy of CD388, a Novel Drug–Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study

Journal:

Clinical Infectious Diseases

Published:

2025-10-08

DOI:

10.1093/cid/ciaf465

Affiliations:

5

Authors:

13

Go to article

Institutions	Authors	Share
Janssen Research & Development (J&J PRD), Belgium	4.000000	0.31
hVIVO Services Limited, United Kingdom (UK)	3.000000	0.23
Johnson & Johnson, United States of America (USA)	2.000000	0.15
Cidara Therapeutics, Inc., United States of America (USA)	2.000000	0.15
Venn Life Sciences - France, France	2.000000	0.15

Interested in Clinical Sciences?